Symbols / APVO
APVO Chart
About
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 10.74M |
| Enterprise Value | -9.83M | Income | -27.95M | Sales | — |
| Book/sh | 22.67 | Cash/sh | 22.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 37 | IPO | — |
| P/E | 0.00 | Forward P/E | -0.24 | PEG | — |
| P/S | — | P/B | 0.30 | P/C | — |
| EV/EBITDA | 0.37 | EV/Sales | — | Quick Ratio | 3.75 |
| Current Ratio | 4.03 | Debt/Eq | 27.54 | LT Debt/Eq | — |
| EPS (ttm) | 7758.20 | EPS next Y | -28.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 16:00 | ROA | -79.19% |
| ROE | -242.74% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.56M |
| Shs Float | 935.44K | Short Float | 15.26% | Short Ratio | 0.40 |
| Short Interest | — | 52W High | 1440.00 | 52W Low | 5.94 |
| Beta | 1.48 | Avg Volume | 185.28K | Volume | 12.34K |
| Target Price | $378.00 | Recom | None | Prev Close | $6.45 |
| Price | $6.88 | Change | 6.67% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$378.00
Mean price target
2. Current target
$6.88
Latest analyst target
3. DCF / Fair value
$-185.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.88
Low
$378.00
High
$378.00
Mean
$378.00
- Biotech lines up $60M to keep next-wave cancer drugs moving to 2029 - Stock Titan Fri, 09 Jan 2026 08
- $APVO stock is down 9% today. Here's what we see in our data. - Quiver Quantitative ue, 09 Dec 2025 08
- Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance Wed, 19 Nov 2025 08
- Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity - TipRanks hu, 19 Feb 2026 11
- Aptevo Therapeutics Announces CEO Transition and Leadership Changes - The Globe and Mail Wed, 04 Feb 2026 08
- Aptevo Therapeutics stock soars after 100% remission rate in AML trial - Investing.com ue, 16 Sep 2025 07
- Aptevo Therapeutics Prospectus Relates To Offer And Sale Of Up To 7,075,471 Shares Of Our Common Stock By Selling Stockholder - TradingView Wed, 28 Jan 2026 08
- Biotech firm turns every 18 shares into 1 in year-end stock move - Stock Titan Fri, 26 Dec 2025 08
- Insider Purchase: Director at $APVO Buys 13,513 Shares - Quiver Quantitative Wed, 12 Nov 2025 08
- Why Is Aptevo Therapeutics Stock (APVO) Up 85% Today? - TipRanks hu, 18 Sep 2025 07
- Aptevo Therapeutics (NASDAQ: APVO) shows 100% CRS-free safety, 87% CR/CRi in AML - Stock Titan ue, 09 Dec 2025 08
- Aptevo (NASDAQ: APVO) extends cash runway to 4Q26 on $18.7M raise and business update - Stock Titan hu, 06 Nov 2025 08
- Aptevo Therapeutics (NASDAQ: APVO) presents APVO451 data: T-cell and APC activation in nectin-4 tumors - Stock Titan Mon, 10 Nov 2025 08
- Interim RAINIER results: Aptevo to present Phase 1b/2 AML data at ASH, SITC, BIO-Europe and ROTH this fall - Stock Titan Wed, 08 Oct 2025 07
- 100% Remission Rate: Aptevo's Novel AML Drug Shows Perfect Response in Latest Trial Cohort, Zero Toxicity - Stock Titan ue, 16 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 13513 | 20134.0 | — | Purchase at price 1.49 per share. | GRANT GRADY III | Director | — | 2025-11-10 00:00:00 | D |
| 1 | 1 | nan | — | — | HARSANYI ZSOLT | Director | — | 2025-07-17 00:00:00 | D |
| 2 | 3 | nan | — | — | TAYLOR DAPHNE L | Chief Financial Officer | — | 2025-07-17 00:00:00 | D |
| 3 | 10 | nan | — | — | WHITE MARVIN L | Chief Executive Officer | — | 2025-07-17 00:00:00 | D |
| 4 | 1 | nan | — | — | NIEDERHUBER JOHN | Director | — | 2025-07-17 00:00:00 | D |
| 5 | 5 | nan | — | — | LAMOTHE JEFFREY G | Chief Operating Officer | — | 2025-07-17 00:00:00 | D |
| 6 | 1 | nan | — | — | GRANT GRADY III | Director | — | 2025-07-17 00:00:00 | D |
| 7 | 1 | nan | — | — | KUNZ BARBARA LOPEZ | Director | — | 2025-07-17 00:00:00 | D |
| 8 | 1 | nan | — | — | ABDUN-NABI DANIEL J | Director | — | 2025-07-17 00:00:00 | D |
| 9 | 3 | nan | — | — | KWON SOYOUNG | General Counsel | — | 2025-07-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -24.25M | -37.96M | -27.74M | -20.26M |
| TotalUnusualItems | 0.00 | 9.65M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 9.65M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.13M | -18.65M | 7.01M | -29.41M |
| ReconciledDepreciation | 352.00K | 567.00K | 901.00K | 1.14M |
| EBITDA | -24.25M | -28.31M | -27.74M | -20.26M |
| EBIT | -24.60M | -28.88M | -28.64M | -21.40M |
| NormalizedIncome | -24.13M | -28.30M | 7.01M | -29.41M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.13M | -17.41M | 8.03M | -28.46M |
| TotalExpenses | 24.60M | 28.88M | 31.75M | 33.69M |
| TotalOperatingIncomeAsReported | -24.60M | -28.88M | -28.64M | -21.40M |
| DilutedAverageShares | 4.05K | 33.00 | 11.00 | 8.00 |
| BasicAverageShares | 4.05K | 33.00 | 11.00 | 8.00 |
| DilutedEPS | -5.96K | -527.61K | 729.73K | -3.56M |
| BasicEPS | -5.96K | -527.61K | 729.73K | -3.56M |
| DilutedNIAvailtoComStockholders | -24.13M | -17.41M | 8.03M | -28.46M |
| NetIncomeCommonStockholders | -24.13M | -17.41M | 8.03M | -28.46M |
| NetIncome | -24.13M | -17.41M | 8.03M | -28.46M |
| NetIncomeIncludingNoncontrollingInterests | -24.13M | -17.41M | 8.03M | -28.46M |
| NetIncomeDiscontinuousOperations | 0.00 | 1.24M | 1.01M | 951.00K |
| NetIncomeContinuousOperations | -24.13M | -18.65M | 7.01M | -29.41M |
| PretaxIncome | -24.13M | -18.65M | 7.01M | -29.41M |
| OtherIncomeExpense | 472.00K | 10.23M | 35.66M | -8.01M |
| OtherNonOperatingIncomeExpenses | 472.00K | 578.00K | 35.66M | -8.01M |
| SpecialIncomeCharges | 0.00 | 9.65M | 0.00 | 0.00 |
| GainOnSaleOfPPE | 0.00 | 9.65M | 0.00 | |
| OtherSpecialCharges | -37.18M | |||
| OperatingIncome | -24.60M | -28.88M | -28.64M | -21.40M |
| OperatingExpense | 24.60M | 28.88M | 31.75M | 33.69M |
| ResearchAndDevelopment | 14.38M | 17.11M | 17.88M | 18.99M |
| SellingGeneralAndAdministration | 10.22M | 11.77M | 13.87M | 14.70M |
| GeneralAndAdministrativeExpense | 10.22M | 11.77M | 13.87M | 14.70M |
| OtherGandA | 10.22M | 11.77M | 13.87M | 14.70M |
| TotalRevenue | 0.00 | 0.00 | 3.11M | 12.29M |
| OperatingRevenue | 0.00 | 0.00 | 3.11M | 12.29M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 4.05K | 33.00 | 11.00 | 8.00 |
| ShareIssued | 4.05K | 33.00 | 11.00 | 8.00 |
| TotalDebt | 4.63M | 5.40M | 9.54M | 16.71M |
| TangibleBookValue | 4.75M | 12.22M | 17.97M | 1.22M |
| InvestedCapital | 4.75M | 12.22M | 21.43M | 16.59M |
| WorkingCapital | 4.45M | 11.84M | 18.74M | 17.81M |
| NetTangibleAssets | 4.75M | 12.22M | 17.97M | 1.22M |
| CapitalLeaseObligations | 4.63M | 5.40M | 6.08M | 1.34M |
| CommonStockEquity | 4.75M | 12.22M | 17.97M | 1.22M |
| TotalCapitalization | 4.75M | 12.22M | 19.43M | 4.92M |
| TotalEquityGrossMinorityInterest | 4.75M | 12.22M | 17.97M | 1.22M |
| StockholdersEquity | 4.75M | 12.22M | 17.97M | 1.22M |
| RetainedEarnings | -247.58M | -223.45M | -206.04M | -214.06M |
| AdditionalPaidInCapital | 252.25M | 235.61M | 223.96M | 215.23M |
| CapitalStock | 84.00K | 61.00K | 48.00K | 47.00K |
| CommonStock | 84.00K | 61.00K | 48.00K | 47.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 10.84M | 12.62M | 16.24M | 55.38M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.63M | 5.40M | 7.54M | 20.63M |
| OtherNonCurrentLiabilities | 15.58M | |||
| LongTermDebtAndCapitalLeaseObligation | 4.63M | 5.40M | 7.54M | 5.05M |
| LongTermCapitalLeaseObligation | 4.63M | 5.40M | 6.08M | 1.34M |
| LongTermDebt | 1.46M | 3.71M | ||
| CurrentLiabilities | 6.21M | 7.22M | 8.71M | 34.76M |
| OtherCurrentLiabilities | 1.30M | 1.14M | 1.10M | 17.55M |
| CurrentDebtAndCapitalLeaseObligation | 2.00M | 11.67M | ||
| CurrentDebt | 2.00M | 11.67M | ||
| OtherCurrentBorrowings | 2.00M | 11.67M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.86M | 2.10M | 2.10M | 2.08M |
| PayablesAndAccruedExpenses | 3.05M | 3.98M | 3.50M | 3.46M |
| TotalAssets | 15.59M | 24.84M | 34.22M | 56.60M |
| TotalNonCurrentAssets | 4.93M | 5.78M | 6.76M | 4.03M |
| OtherNonCurrentAssets | 68.00K | |||
| NetPPE | 4.93M | 5.78M | 6.76M | 3.96M |
| AccumulatedDepreciation | -13.95M | -13.59M | -13.03M | -12.28M |
| GrossPPE | 18.88M | 19.37M | 19.79M | 16.24M |
| Leases | 2.23M | 2.23M | 2.23M | 2.23M |
| OtherProperties | 7.00K | |||
| MachineryFurnitureEquipment | 12.26M | 12.26M | 12.26M | 12.43M |
| BuildingsAndImprovements | 4.39M | 4.88M | 5.30M | 1.58M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 10.66M | 19.07M | 27.45M | 52.57M |
| OtherCurrentAssets | 256.00K | 689.00K | 744.00K | 780.00K |
| RestrictedCash | 0.00 | 1.26M | ||
| PrepaidAssets | 1.69M | 1.47M | 1.57M | 1.82M |
| Receivables | 0.00 | 2.50M | 3.66M | |
| OtherReceivables | 2.50M | 3.66M | ||
| CashCashEquivalentsAndShortTermInvestments | 8.71M | 16.90M | 22.64M | 45.04M |
| CashAndCashEquivalents | 8.71M | 16.90M | 22.64M | 45.04M |
| CashEquivalents | 7.53M | 13.17M | 21.57M | 41.20M |
| CashFinancial | 1.18M | 3.73M | 1.07M | 3.84M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -23.79M | -11.73M | -21.05M | -22.39M |
| RepaymentOfDebt | 0.00 | -3.47M | -12.27M | -10.55M |
| IssuanceOfCapitalStock | 10.04M | 6.43M | 6.93M | 10.23M |
| CapitalExpenditure | -29.00K | -713.00K | ||
| EndCashPosition | 8.71M | 16.90M | 22.64M | 46.30M |
| BeginningCashPosition | 16.90M | 22.64M | 46.30M | 42.53M |
| ChangesInCash | -8.19M | -5.73M | -23.67M | 3.77M |
| FinancingCashFlow | 15.60M | 6.00M | -2.62M | 26.16M |
| CashFlowFromContinuingFinancingActivities | 15.60M | 6.00M | -2.62M | 26.16M |
| NetOtherFinancingCharges | -4.00K | -10.00K | 2.72M | 25.27M |
| ProceedsFromStockOptionExercised | 5.56M | 3.05M | 0.00 | 1.21M |
| NetCommonStockIssuance | 10.04M | 6.43M | 6.93M | 10.23M |
| CommonStockIssuance | 10.04M | 6.43M | 6.93M | 10.23M |
| NetIssuancePaymentsOfDebt | 0.00 | -3.47M | -12.27M | -10.55M |
| NetLongTermDebtIssuance | 0.00 | -3.47M | -12.27M | -10.55M |
| LongTermDebtPayments | 0.00 | -3.47M | -12.27M | -10.55M |
| InvestingCashFlow | 0.00 | 0.00 | -29.00K | -713.00K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -29.00K | -713.00K | |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | 0.00 | -29.00K | -713.00K | |
| PurchaseOfPPE | 0.00 | -29.00K | -713.00K | |
| OperatingCashFlow | -23.79M | -11.73M | -21.02M | -21.68M |
| CashFlowFromContinuingOperatingActivities | -23.79M | -11.73M | -21.02M | -21.68M |
| ChangeInWorkingCapital | -1.08M | 2.91M | 2.14M | -2.65M |
| ChangeInOtherCurrentLiabilities | -768.00K | -682.00K | 366.00K | -1.02M |
| ChangeInOtherCurrentAssets | 492.00K | 422.00K | 653.00K | 1.14M |
| ChangeInPayablesAndAccruedExpense | -1.02M | 518.00K | -394.00K | -1.92M |
| ChangeInPayable | -1.02M | 518.00K | -394.00K | -1.92M |
| ChangeInAccountPayable | -1.02M | 518.00K | -394.00K | -1.92M |
| ChangeInPrepaidAssets | 217.00K | 153.00K | 355.00K | 436.00K |
| ChangeInReceivables | 0.00 | 2.50M | 1.16M | -1.29M |
| OtherNonCashItems | 10.00K | -33.94M | 6.64M | |
| StockBasedCompensation | 1.07M | 2.19M | 1.80M | 1.64M |
| DepreciationAmortizationDepletion | 352.00K | 567.00K | 901.00K | 1.14M |
| DepreciationAndAmortization | 352.00K | 567.00K | 901.00K | 1.14M |
| OperatingGainsLosses | 47.00K | 4.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 47.00K | 4.00K | |
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -24.13M | -17.41M | 8.03M | -28.46M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for APVO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|